Molecular mechanisms, crosstalk and therapeutic potential of novel acylation modifications in cardiovascular and cerebrovascular diseases.
- 1School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China.
Abstract
Metabolic reprogramming, the fundamental process by which cells adapt to fluctuations in energy demands, is pivotal in the pathophysiology of cardiovascular and cerebrovascular diseases (CCVDs). Aberrant reprogramming of glucose, lipid, and amino acid metabolism is intricately associated with pathological processes in CCVDs such as cardiac hypertrophy, atherosclerosis, and ischemia-reperfusion injury. This metabolic remodeling disrupts the dynamic balance of metabolites (cc, acetyl-CoA and lactate) in the cardio-cerebrovascular systems, thereby inducing abnormal post-translational modifications (PTMs) on histones and non-histone proteins. These PTMs drive disease progression by modulating gene transcription or the activity of key proteins, which subsequently influences downstream signaling pathways. Here, we systematically examine the regulatory enzymes and functional roles of nine recently characterized acylation modifications: crotonylation, β-hydroxybutyrylation, 2-hydroxyisobutyrylation, succinylation, malonylation, glutarylation, lactylation, propionylation, and butyrylation. Furthermore, this review elaborates on the molecular mechanisms, crosstalk and the latest preclinical advancements regarding these acylations in CCVDs, emphasizing the influence of distinct acylation patterns on various pathological processes and highlighting the clinical translational prospects of targeting these novel modifications for therapeutic intervention.
Related
- The Role of Neutrophil Extracellular Traps (NETosis) in Systemic Lupus Erythematosus: Molecular Mechanisms, Pathogenic Roles, Diagnostic Biomarkers, and Emerging Therapeutic Strategies
- The m6A methyltransferase METTL3 in intervertebral disc degeneration: from molecular mechanisms to therapeutic potential
- Extracellular Vesicles in Molecular Crosstalk and Disease Pathogenesis: A Comprehensive Review on Mechanisms and Therapeutic Prospects
- Special Issue “Molecular Mechanisms and Therapeutic Targets in Skin Diseases”
- AAV9 Gene Therapy for Ovarian Dysfunction and Reproductive Aging: Molecular Mechanisms, Therapeutic Targets, and Translational Perspectives
BibTeX
@article{li2026molecular,
title = {{Molecular mechanisms, crosstalk and therapeutic potential of novel acylation modifications in cardiovascular and cerebrovascular diseases.}},
author = {Wanchun Li and Weile Ye and Jiaojiao Wang and Zhiping Liu},
journal = {Acta pharmaceutica Sinica. B},
year = {2026},
month = jun,
doi = {10.1016/j.apsb.2026.06.051},
url = {https://europepmc.org/article/MED/42948374},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Molecular mechanisms, crosstalk and therapeutic potential of novel acylation modifications in cardiovascular and cerebrovascular diseases.
AU - Wanchun Li
AU - Weile Ye
AU - Jiaojiao Wang
AU - Zhiping Liu
PY - 2026
DA - 2026/06/29
JO - Acta pharmaceutica Sinica. B
DO - 10.1016/j.apsb.2026.06.051
UR - https://europepmc.org/article/MED/42948374
AB - Metabolic reprogramming, the fundamental process by which cells adapt to fluctuations in energy demands, is pivotal in the pathophysiology of cardiovascular and cerebrovascular diseases (CCVDs). Aberrant reprogramming of glucose, lipid, and amino acid metabolism is intricately associated with pathological processes in CCVDs such as cardiac hypertrophy, atherosclerosis, and ischemia-reperfusion injury. This metabolic remodeling disrupts the dynamic balance of metabolites (cc, acetyl-CoA and lactate) in the cardio-cerebrovascular systems, thereby inducing abnormal post-translational modifications (PTMs) on histones and non-histone proteins. These PTMs drive disease progression by modulating gene transcription or the activity of key proteins, which subsequently influences downstream signaling pathways. Here, we systematically examine the regulatory enzymes and functional roles of nine recently characterized acylation modifications: crotonylation, β-hydroxybutyrylation, 2-hydroxyisobutyrylation, succinylation, malonylation, glutarylation, lactylation, propionylation, and butyrylation. Furthermore, this review elaborates on the molecular mechanisms, crosstalk and the latest preclinical advancements regarding these acylations in CCVDs, emphasizing the influence of distinct acylation patterns on various pathological processes and highlighting the clinical translational prospects of targeting these novel modifications for therapeutic intervention.
SN - 2211-3835
SN - 2211-3843
ER -